We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Greater Flexibility May Make U.S. A Magnet for New Biosimilars
Greater Flexibility May Make U.S. A Magnet for New Biosimilars
April 6, 2012
Companies seeking to market biosimilars may have more success getting their products approved in the U.S. than in other highly regulated markets, thanks to “step-wise” guidance developed by the U.S. Food and Drug Administration (FDA) and released in February.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor